By: Kerri Fitzgerald
The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in patients with newly diagnosed multiple myeloma (MM) compared with VRd alone.
The study was presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting.
The study included 395 transplant-ineligible or -deferred patients who received D-VRd (n=144) or VRd (n=145).
The measurable residual disease (MRD)-negativity rate at 10−5 was 60.4% in the D-VRd group versus 39.3% in the VRd cohort (odds ratio [OR], 2.37; P<0.0001). The MRD-negativity rate at 10−6 was 45.8% and 26.9%, respectively (OR, 2.28; P=0.001). MRD-negativity was sustained (at the 10−5 threshold) in 46.5% of the D-VRd group and 27.6% of the VRd group (OR, 2.27; P=0.0010).
A greater proportion of patients achieved a complete response or better in the D-VRd group (80.6% vs 61.4%; OR, 2.73; P<0.0001).
After approximately 4.5 years of follow-up, median progression-free survival was not reached in the D-VRd group versus 49.6 months in the VRd cohort. Overall survival favored D-VRd versus VRd (hazard ratio, 0.66).
The researchers said safety outcomes “aligned with known safety profiles for subcutaneous daratumumab and VRd.”
“These data demonstrate the strong efficacy of D-VRd in [transplant-ineligible] patients,” they concluded.
This abstract was accepted and previously presented at the 2025 ASCO Annual Meeting.
Reference
Usmani SZ, Zweegman S, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) in patients with newly diagnosed multiple myeloma (NDMM): subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study. Abstract #MM-771. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, Texas.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
